# Range Cancer Therapeutics ETF

Range Cancer Therapeutics ETF is a ETF series of ETF Series Solutions (series S000050740). Net assets $8.9M as of 2025-02-28. Index fund.

## Profile

- Series ID: S000050740
- Registrant: ETF Series Solutions
- LEI: 549300MLI82YH9HOGS11
- Net assets: $8.9M
- Total assets: $8.9M
- As of: 2025-02-28
- Type: ETF, Index

## Advisers

- [Exchange Traded Concept, LLC (Advisor)](https://search.stillhousedata.com/firm/151197)
- [Vident Investment Advisory, LLC (Subadvisor)](https://search.stillhousedata.com/firm/171004)

## Top holdings (76 reported)

_Showing 15 of 76 holdings by value._

| Holding | Ticker | Value | % of fund |
| --- | --- | --- | --- |
| [Recursion Pharmaceuticals Inc](https://search.stillhousedata.com/security/75629V104) | — | $358K | 401.29% |
| [Precigen Inc](https://search.stillhousedata.com/security/74017N105) | — | $272K | 305.02% |
| [Compass Therapeutics Inc](https://search.stillhousedata.com/security/20454B104) | — | $267K | 298.95% |
| [Genelux Corp](https://search.stillhousedata.com/security/36870H103) | — | $259K | 290.10% |
| [SpringWorks Therapeutics Inc](https://search.stillhousedata.com/security/85205L107) | — | $256K | 286.33% |
| [Exelixis Inc](https://search.stillhousedata.com/security/30161Q104) | — | $222K | 248.31% |
| [Ginkgo Bioworks Holdings Inc](https://search.stillhousedata.com/security/37611X209) | — | $208K | 233.16% |
| [Replimune Group Inc](https://search.stillhousedata.com/security/76029N106) | — | $191K | 213.70% |
| [Bristol-Myers Squibb Co](https://search.stillhousedata.com/security/110122108) | — | $188K | 210.28% |
| [Schrodinger Inc/United States](https://search.stillhousedata.com/security/80810D103) | — | $177K | 198.03% |
| [Blueprint Medicines Corp](https://search.stillhousedata.com/security/09627Y109) | — | $176K | 197.29% |
| [Zymeworks Inc](https://search.stillhousedata.com/security/98985Y108) | — | $169K | 188.82% |
| [Vor BioPharma Inc](https://search.stillhousedata.com/security/929033108) | — | $168K | 188.49% |
| [HUTCHMED China Ltd](https://search.stillhousedata.com/security/44842L103) | — | $157K | 175.55% |
| [Innate Pharma SA](https://search.stillhousedata.com/security/45781K204) | — | $154K | 172.61% |

## Net asset history

| Report date | Net assets |
| --- | --- |
| 2025-02-28 | $8.9M |
| 2024-11-30 | $11.9M |
| 2024-08-31 | $13.3M |
| 2024-05-31 | $16.5M |
| 2024-02-29 | $19.4M |
| 2023-11-30 | $11.3M |
| 2023-08-31 | $9.6M |
| 2023-05-31 | $13.3M |

## More

- [Registrant: ETF Series Solutions](https://search.stillhousedata.com/registrant/1540305)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/fund/S000050740.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.